Abstract: . . .  complications or vascular surgical complications complications or vascular surgical complications Leon et al. NEJM 1998;339:1665-1671. Page 19 STARS STARS MACE * MACE * (p=0.001) (p=0.001) Bleeding Bleeding (p<0.001) (p<0.001) Vascular Vascular (p=0.02) (p=0.02) Asa Asa 3.6% 3.6% 1.8% 1.8% 0.4 0.4 Asa Asa + + Warfarin Warfarin 2.7% 2.7% 6.2% 6.2% 2.0 2.0 Asa Asa + + Ticlopidine Ticlopidine 0.5% 0.5% 5.5% 5.5% 2.0 2.0 Leon et al. NEJM 1998;339:1665-1671. Page 20 The Full Anticoagulation Vs The Full Anticoagulation Vs Aspirin and Aspirin and Ticlopidine Ticlopidine Study (FANTASTIC) Study (FANTASTIC) Multicenter Multicenter , randomized , randomized Warfarin Warfarin vs vs asa asa + + ticlopidine ticlopidine 1 1 o o endpoint: bleeding or peripheral endpoint: bleeding or peripheral vascular complications vascular complications 2 2 o o endpoint: cardiac events (death, endpoint: cardiac events (death, MI, MI, stent stent occlusion) and duration of occlusion) and duration of hospitalization hospitalization Bertrand et al. Circ 1998;98:1597-1603. Page 21 FANTASTIC FANTASTIC Bertrand et al. Circ 1998;98:1597-1603. Primary Endpoints Page 22 FANTASTIC FANTASTIC Bertrand et al. Circ 1998;98:1597-1603. Secondary Endpoints Page 23 Tcheng. Am Heart J 1999;138:602-5. Page 24 Stent Stent Thrombosis in the Thrombosis in the Modern Era Modern Era 6 trials pooled 6 trials pooled 6186 patients 6186 patients 2 2 nd nd generation generation stents stents High pressure inflation High pressure inflation Aspirin + Aspirin + ticlopidine ticlopidine Cutlip et al. Circ 2001;103:1967-1971. Page 25 Stent Stent Thrombosis in the Thrombosis in the Modern Era Modern Era 53 patients (0.9%) developed . . .
--3000,1,1500,3101,23701